Due to the impressive accumulation of out-standing results, presented by brilliant, privileged and creative thinkers, this unique book reads like the 'Who is Who' of biotechnology. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel Prize laureates Robert Huber, Thomas R. Cech, and Manfred Eigen as well as authors from the world's most famous academic institutes and biotech companies, such as ETH Zurich, MIT, Stanford, Yale, Princeton, Harvard Medical School, Max-Planck-Institute, Fraunhofer-Institute, Moscow Academy of Sciences, London Imperial College and Baxter, Invitrogen, MorphoSys, Roche, and Schering AG. Published as a comprehensive four volume set, this title also includes a CD-ROM containing additional information and videos. "Modern Biopharmaceuticals" describes: the first cloned human embryo; the first myocardial regeneration with embryonic stem cells; the first artificial kidney; the first biopharmaceutical from a transgenic animal; the first individualized medicine; the first plasma-free Factor VIII; the first approved human cell line; and, the first oral insulin, etc. '...an outstanding collection of articles from groundbreaking scientists, comprehensively describing the many novel ways cells are being deployed toward human good . ..' - James D. Watson, 'DNA Codebreaker' and Nobel Prize Laureate (Physiology or Medicine, 1962). "Modern Biopharmaceuticals" is an essential reference work for biotechnologists, clinicians, medical doctors, pharmacists, pharmaceutical chemists, bio-chemists, molecular biologists, medicinal chemists, as well as all those working in the biotechnological and pharmaceutical industries, or medicinal institutes.

This collection of high-profile contributions provides a unique insight into the development of novel, successful biopharmaceuticals.

Outstanding authors, including Nobel laureate Robert Huber as well as prominent company researchers and CEOs, present valuable insider knowledge, limiting their scope to those procedures and developments with proven potential for the biotechnology industry. They cover all relevant aspects, from the establishment of biotechnology parks, the development of successful compounds and the implementation of efficient manufacturing processes, right up to the establishment of advanced delivery routes.